Introduction
The landscape of catheter ablation for atrial fibrillation (AF) is undergoing a paradigm shift. For decades, thermal energy—primarily radiofrequency ablation (RFA) and cryoballoon ablation—has been the cornerstone of pulmonary vein isolation (PVI). However, thermal modalities carry inherent risks of collateral tissue damage, including esophageal injury, phrenic nerve palsy, and pulmonary vein stenosis, due to their non-selective nature. Pulsed field ablation (PFA), a non-thermal modality utilizing high-voltage, ultra-short electrical pulses to induce irreversible electroporation, has emerged as a promising alternative with high myocardial selectivity. The InsightPFA trial evaluates a next-generation iteration of this technology: nanosecond pulsed field ablation (nsPFA). By utilizing pulses in the nanosecond range rather than the microsecond range, this novel system aims to further refine the precision and efficiency of PVI.
